Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial (Q45405108)

From Wikidata

Jump to navigation Jump to search

scientific article published in April 2007

edit

Language	Label	Description	Also known as
English	Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial	scientific article published in April 2007

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17434401

retrieved

14 December 2017

title

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17434401

retrieved

14 December 2017

main subject

phase II clinical trial

0 references

patient

0 references

multiple drug resistance

1 reference

based on heuristic

inferred from title

raltegravir

1 reference

based on heuristic

inferred from title

author

Christine Katlama

series ordinal

3

object named as

Christine Katlama

0 references

Adriano Lazzarin

object named as

Adriano Lazzarin

series ordinal

5

0 references

Beatriz Grinsztejn

series ordinal

1

object named as

Beatriz Grinsztejn

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17434401

retrieved

14 December 2017

author name string

Bach-Yen Nguyen

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17434401

retrieved

14 December 2017

Jose M Gatell

series ordinal

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17434401

retrieved

14 December 2017

Daniel Vittecoq

series ordinal

6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17434401

retrieved

14 December 2017

Charles J Gonzalez

series ordinal

7

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17434401

retrieved

14 December 2017

Joshua Chen

series ordinal

8

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17434401

retrieved

14 December 2017

Charlotte M Harvey

series ordinal

9

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17434401

retrieved

14 December 2017

Robin D Isaacs

series ordinal

10

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17434401

retrieved

14 December 2017

Protocol 005 Team

series ordinal

11

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17434401

retrieved

14 December 2017

language of work or name

English

0 references

publication date

1 April 2007

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17434401

retrieved

14 December 2017

published in

The Lancet

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17434401

retrieved

14 December 2017

volume

369

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17434401

retrieved

14 December 2017

issue

9569

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17434401

retrieved

14 December 2017

page(s)

1261-1269

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17434401

retrieved

14 December 2017

cites work

Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960597-2

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Emerging anti-HIV drugs

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960597-2

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Screening and selecting for optimized antiretroviral drugs: rising to the challenge of drug resistance

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960597-2

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of drug resistance on viral load in patients failing antiretroviral therapy

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960597-2

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

New antiretroviral drugs

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960597-2

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

The prevalence of antiretroviral drug resistance in the United States

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960597-2

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Human immunodeficiency virus type 1 (HIV-1) genotyping in Rio de Janeiro, Brazil: assessing subtype and drug-resistance associated mutations in HIV-1 infected individuals failing highly active antiretroviral therapy

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960597-2

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960597-2

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960597-2

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug r

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960597-2

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960597-2

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960597-2

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

DOI

10.1016/S0140-6736(07)60597-2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17434401

retrieved

14 December 2017

PubMed publication ID

17434401

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17434401

retrieved

14 December 2017

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45405108&oldid=2076646236"